SELECTION OF STAPHYLOCOCCAL IMMUNOGENES TO OBTAIN HYPERIMMUNE POLYCLONAL SERUM
This work was supported by Shota Rustaveli National Science Foundation of Georgia (SRNSFG), Grant # AR - 18-306
Keywords:staphylococcus, anatoxin, PV-leukocidin, anti-staphylococcal serum
Complicated staphylococcal infections: sepsis, meningitis, endocarditis and other requires the development of new generation biological agent with high medicinal property, devoid of adverse events. In this direction, development of microbial cell antigen, anti-hemolytic, anti-leukocidin and anti-hyaluronidase immunoglobulin is promising, which needs staphylococcal immunogene for immunization of producers. Selection of staphylococcal strains was based on the study of morphological, cultural and enzymatic activity, determination of sensitivity to novobiocin and staphylococcal bacteriophage. Among 102 laboratory and clinical staphylococcal strains, following were selected: a) high plasmocoagulating, with hemolytic property, mannitol decomposition and proteolytic property, also St. aureus 24 sensitive to novobiocin and staphylophage and St. epidermidis 6 strains devoid of the mentioned property; b) Thermally inactivated staphylococcal strains, due to their stable characteristics; c) Staphylococcal: alfa-anatoxin, PV-leukocidin and hyaluronidase. Mentioned immunogens were used for priming and immunization of producer-animals (goats). First cycle of immunization has been administered. In the immune serum, the activity of antibodies against the used immunogens is determined by immunoenzymatic analysis, based on „Sandwich-ELISA“ and in passive hemagglutination reaction, using diagnostic test-systems.
Bröker BM, Mrochen D, Péton V. The T Cell Response to Staphylococcus aureus. Pathogens. 2016 Mar 17;5(1):31. doi: 10.3390/pathogens5010031. PMID: 26999219; PMCID: PMC4810152.
Cohen TS, Hilliard JJ, Jones-Nelson O, Keller AE, et al. Staphylococcus aureus α toxin potentiates opportunistic bacterial lung infections. Sci Transl Med. 2016 Mar 9;8(329):329ra31. doi: 10.1126/scitranslmed.aad9922. PMID: 26962155.
Colque-Navarro P, Jacobsson G, Andersson R, Flock JI, Möllby R. Levels of antibody against 11 Staphylococcus aureus antigens in a healthy population. Clin Vaccine Immunol. 2010 Jul;17(7):1117-23. doi: 10.1128/CVI.00506-09. PMID: 20445005; PMCID: PMC2897265.
Deng J, Wang X, et al. Broad and Effective Protection against Staphylococcus aureus Is Elicited by a Multivalent Vaccine Formulated with Novel Antigens. mSphere. 2019 Sep 4;4(5):e00362-19. doi: 10.1128/mSphere.00362-19. PMID: 31484738; PMCID: PMC6731528.
Larkin EA, Stiles BG, Ulrich RG. Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One. 2010 Oct 11; 5(10):e13253. doi: 10.1371/journal.pone.0013253. PMID: 20949003; PMCID: PMC2952590.
Liu C, Bayer A, Cosgrove SE, Daum RS, et al. Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 1;52(3):e18-55. doi: 10.1093/cid/ciq146. PMID: 21208910.
Ohlsen K, Lorenz U. Immunotherapeutic strategies to combat staphylococcal infections. Int J Med Microbiol. 2010 Aug;300(6):402-10. doi: 10.1016/j.ijmm.2010.04.015. PMID: 20547101.
Thomer L, Emolo C, et al. Antibodies against a secreted product of Staphylococcus aureus trigger phagocytic killing. J Exp Med. 2016 Mar 7;213(3):293-301. doi: 10.1084/jem.20150074. PMID: 26880578; PMCID: PMC4813671